Oral antineoplastic agent interactions with medicinal plants and food: an issue to take into account

Roberto Collado-Borrell1, Vicente Escudero-Vilaplana2, Rosa Romero-Jiménez1

  • 1Pharmacy Department, Gregorio Marañón General University Hospital, Madrid, Spain.

Abstract

Insights

Over half of oral antineoplastic agents (OAAs) interact with common foods and medicinal plants. Healthcare professionals should consider these interactions, especially with St. John's wort, grapefruit, ginseng, and tobacco, to ensure safe and effective cancer treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Integrative Medicine

Background:

  • Oral antineoplastic agents (OAAs) are increasingly used for cancer treatment.
  • Interactions between OAAs and dietary components can affect treatment efficacy and safety.
  • Limited comprehensive reviews exist on OAA interactions with common foods and medicinal plants.

Purpose of the Study:

  • To systematically review and document interactions between OAAs and common foods and medicinal plants.
  • To identify specific OAAs, foods, and medicinal plants with significant interaction potential.
  • To provide evidence-based support for healthcare professionals managing OAA therapy.

Main Methods:

  • Literature search of PubMed, Thomson Micromedex, and Lexi-comp for OAA interactions.
  • Inclusion of OAAs approved by the European Medicines Agency (April 2015).
  • Analysis of interactions with medicinal plants and foods, categorizing them by importance.

Main Results:

  • Interactions were identified for 60.3% of the 58 analyzed OAAs.
  • St. John's wort and grapefruit exhibited the highest number of important interactions.
  • Significant interactions were noted with imatinib, procarbazine, erlotinib, and methotrexate.

Conclusions:

  • A substantial proportion of OAAs interact with medicinal plants and foods, with many interactions being clinically important.
  • Awareness of these interactions is crucial for optimizing OAA therapy and patient safety.
  • This review serves as a valuable resource for healthcare providers prescribing or dispensing OAAs.

Related Concept Videos

Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
444
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
275
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
609
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
723
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
778
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
915